Dermata Therapeutics Statistics Share Statistics Dermata Therapeutics has 637.81K
shares outstanding. The number of shares has increased by 322.34%
in one year.
Shares Outstanding 637.81K Shares Change (YoY) 322.34% Shares Change (QoQ) 17.45% Owned by Institutions (%) 38.16% Shares Floating 499.86K Failed to Deliver (FTD) Shares 1,792 FTD / Avg. Volume 12.08%
Short Selling Information The latest short interest is 100.68K, so 1.58% of the outstanding
shares have been sold short.
Short Interest 100.68K Short % of Shares Out 1.58% Short % of Float 2.25% Short Ratio (days to cover) 1
Valuation Ratios PE Ratio 0 Forward PE -0.59 PS Ratio 0 Forward PS 0.3 PB Ratio 0 P/FCF Ratio -0.02 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Dermata Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.79,
with a Debt / Equity ratio of 0.
Current Ratio 1.79 Quick Ratio 1.79 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.54B Employee Count 8 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 168.72% in the
last 52 weeks. The beta is 0.56, so Dermata Therapeutics's
price volatility has been higher than the market average.
Beta 0.56 52-Week Price Change 168.72% 50-Day Moving Average 3.99 200-Day Moving Average 1.84 Relative Strength Index (RSI) 57.53 Average Volume (20 Days) 14,829
Income Statement
Revenue n/a Gross Profit n/a Operating Income -12.51B Net Income -12.29B EBITDA -12.29M EBIT -12.29M Earnings Per Share (EPS) -80322.2
Full Income Statement Balance Sheet The company has 3.16M in cash and 0 in
debt, giving a net cash position of 3.16M.
Cash & Cash Equivalents 3.16M Total Debt n/a Net Cash n/a Retained Earnings -65.68M Total Assets 10.01M Working Capital 7.3M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -11.16M
and capital expenditures 0, giving a free cash flow of -11.16M.
Operating Cash Flow -11.16M Capital Expenditures n/a Free Cash Flow -11.16M FCF Per Share -72.96
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields DRMA does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for DRMA is $30,
which is 391.8% higher than the current price. The consensus rating is "Buy".
Price Target $30 Price Target Difference 391.8% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 1, 2025. It was a
backward
split with a ratio of 1:10.
Last Split Date Aug 1, 2025 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -12.63 Piotroski F-Score 1
